Aggressive Pituitary Adenomas: The Dark Side of the Moon

Priola, Stefano Maria; Esposito, Felice; Cannavò, Salvatore; Conti, Alfredo; Abbritti, Rosaria; Barresi, Valeria; Baldari, Sergio; Ferraú, Francesco; Germanò, Antonino; Tomasello, Francesco; Angileri, Filippo Flavio

doi:10.1016/j.wneu.2016.09.092

Cited by 39 publications

(33 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tumour uptake was assessed by octreoscan or 68Ga-DOTATATE PET/CT. Four patients were treated with 111Indium-DPTAoctreotide (164,165), 4 with 177Lutetium DOTATATE (25,166,167), 3 with 90Yttrium-DOTATOC (25,168,169) and 3 with 177Lutetium DOTATOC (11,25). Patients received 2-4 cycles.…”

Section: Peptide Receptor Radionuclide Therapy (Pprt)mentioning

confidence: 99%

See 1 more Smart Citation

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

Raverot

Burman

McCormack

et al. 2018

European Journal of Endocrinology

456

583

View full text Add to dashboard Cite

Background: Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with metastases (pituitary carcinoma). The present European Society of Endocrinology (ESE) guideline aims to provide clinical guidance on diagnosis, treatment and follow-up in aggressive pituitary tumours and carcinomas. Methods: We decided upfront, while acknowledging that literature on aggressive pituitary tumours and carcinomas is scarce, to systematically review the literature according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. The review focused primarily on first-and second-line treatment in aggressive pituitary tumours and carcinomas. We included 14 single-arm cohort studies (total number of patients = 116) most on temozolomide treatment (n = 11 studies, total number of patients = 106). A positive treatment effect was seen in 47% (95% CI: 36-58%) of temozolomide treated. Data from the recently performed ESE survey on aggressive pituitary tumours and carcinomas (165 patients) were also used as backbone for the guideline. In patients responding to first-line temozolomide, we suggest continuing treatment for at least 6 months in total. Furthermore, the guideline offers recommendations for patients who recurred after temozolomide treatment, for those who did not respond to temozolomide and for patients with systemic metastasis.

show abstract

Section: Peptide Receptor Radionuclide Therapy (Pprt)mentioning

confidence: 99%

“…Three patients have been reported to have stable disease with follow-up of 1 year and 3.5 years in 2 of these patients (165,166,167). Nine tumours progressed on treatment or shortly after treatment cessation (165,167,169).…”

Section: Peptide Receptor Radionuclide Therapy (Pprt)mentioning

confidence: 99%

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

Raverot

Burman

McCormack

et al. 2018

European Journal of Endocrinology

456

583

View full text Add to dashboard Cite

show abstract

“…«Агрессивность» аденомы гипофиза может быть связа-на с изменением иммунофенотипа, со скрытым про-дуцированием адренокортикотропного, соматотроп-ного и тиреотропного гормонов и повышенным (>15 %) индексом пролиферации. Однако в ряде слу-чаев опухоль не проявляется ни одним из вышеуказан-ных признаков, демонстрируя при этом агрессивный характер роста и рецидивирования [20]. Кроме того, агрессивный характер некоторых аде-ном гипофиза с локальной инвазией окружающих тканей зачастую и вовсе остается незамеченным из-за результатов гистологического исследования, указы-вающего на доброкачественный характер опухоли [26].…”

Section: через 4 года после повторного облучения достигнут практическunclassified

“…В литературе отсутствует стандартное определение агрессивных аденом гипофиза, вследствие чего нет исследований, сообщающих о правильной терапии этого заболевания, за исключением нескольких сооб-щений об использовании темозоломида в качестве «спасительного» лечения у пациентов, не ответивших на традиционные методы [20][21][22][23].…”

Section: Introductionunclassified

Aggressive forms of pituitary adenomas (literature review and clinical observation)

Kalinin¹,

Trunin²,

Fomichev³

et al. 2017

Opuholi golovy šei

View full text Add to dashboard Cite

“…It was estimated that invasive PA is composed of approximately 30% of PA, which is characterized as tumor invading the adjacent sphenoid sinus and cavernous sinus (5,6). Since complete resection is difficult for extensive local invasion, better understanding the molecular mechanisms underlying invasive PA is urgently needed for early diagnosis and treatment (7) Matrix metalloproteinase (MMPs), a family of zinc-containing endopeptidases that can degrade the natural extracellular matrix and basement membrane, allows for the growth and mobility of tumor cells, thereby easily enabling tumor cell proliferation and invasion, including into the PA (8)(9)(10).Tissue inhibitors of metalloproteinases (TIMPs) can non-selectively but effectively inhibit the active MMPs (8)(9)(10) which have been known to act as tumor suppressor genes in several tumors. TIMP2, a possible antagonist of MMP2, is a metastasis suppressor in the process of invasion of cervical cancer cells (11).…”

Section: Introductionmentioning

confidence: 99%

Demethylation of TIMP2 and TIMP3 inhibit cell proliferation, migration and invasion in pituitary adenoma

Yang

Huang

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Pituitary adenoma (PA) is one of the most common intracranial neoplasms. Tissue inhibitors of metalloproteinases (TIMPs) are prognostic biological markers, but their biological roles remains largely unclear in invasive PA. Methods: The promoter methylation status of TIMP2 and TIMP3 genes in invasive PA tissues and cells was measured by methylation-specific polymerase chain reaction (MSP). The expression of TIMP1-3 was validated by quantitative real time PCR and western blot analysis. Overexpression and knockdown of TIMP2 and TIMP3 in GH3 cells were created by transfection of pcDNA3.0 and siRNA against TIMP2 and TIMP3, respectively. Functional experiments in GH3 cells were performed with CCK-8 assay, wound healing assay and transwell assay. Effects of 5-Azacytidene (5-AzaC) on the methylation of TIMP2 and TIMP3 gene, and DNA methyltransferase 1 (DNMT1), DNMT3a and DNMT3b were determined by western blot analysis. Results: We found the expression of TIMP1, TIMP2 and TIMP3 was down-regulated in invasive PA tissues and cells. Moreover, decreased TIMP2 and TIMP3 expression was closely associated with their promoter methylation. The in vitro experiments showed that overexpression of TIMP2 and TIMP3 exerted suppressive effects, while knockdown of TIMP2 and TIMP3 presented enhanced effects on cell proliferation, migration and invasion in PA cells. Furthermore, 5-AzaC treatment concomitantly up-regulated the protein levels of TIMP2, TIMP3, DNMT1, DNMT3a and DNMT3b. Conclusions: In conclusion, our results support that DNA methylation at least partly accounts for TIMP2 or TIMP3 silencing in invasive PA, which will provide new insights into the mechanisms underlying the function of TIMPs in PA. Key words: Invasive pituitary adenoma, TIMPs, DNA methylation, 5-AzaC, GH3

show abstract

Aggressive Pituitary Adenomas: The Dark Side of the Moon

Cited by 39 publications

References 72 publications

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

Aggressive forms of pituitary adenomas (literature review and clinical observation)

Demethylation of TIMP2 and TIMP3 inhibit cell proliferation, migration and invasion in pituitary adenoma

Contact Info

Product

Resources

About